1. Milteforan, a promising veterinary commercial product against feline sporotrichosis.
- Author
-
García Carnero LC, Pinzan CF, Diehl C, de Castro PA, Pontes L, Rodrigues AM, Dos Reis TF, and Goldman GH
- Subjects
- Animals, Cats, Humans, Phosphorylcholine analogs & derivatives, Phosphorylcholine pharmacology, Phosphorylcholine therapeutic use, Brazil, Microbial Sensitivity Tests, Dogs, Macrophages drug effects, Macrophages microbiology, Mice, Sporotrichosis drug therapy, Sporotrichosis microbiology, Sporotrichosis veterinary, Sporothrix drug effects, Antifungal Agents pharmacology, Cat Diseases drug therapy, Cat Diseases microbiology
- Abstract
Sporotrichosis, the cutaneous mycosis most commonly reported in Latin America, is caused by the Sporothrix clinical clade species, including Sporothrix brasiliensis and Sporothrix schenckii sensu stricto . Due to its zoonotic transmission in Brazil, S. brasiliensis represents a significant health threat to humans and domestic animals. Itraconazole, terbinafine, and amphotericin B are the most used antifungals for treating sporotrichosis. However, many strains of S. brasiliensis and S. schenckii have shown resistance to these agents, highlighting the importance of finding new therapeutic options. Here, we demonstrate that milteforan, a commercial veterinary product against dog leishmaniasis, whose active principle is miltefosine, is a possible therapeutic alternative for the treatment of sporotrichosis, as observed by its fungicidal activity in vitro against different strains of S. brasiliensis and S. schenckii . Fluorescent miltefosine localizes to the Sporothrix cell membrane and mitochondria and causes cell death through increased permeabilization. Milteforan decreases S. brasiliensis fungal burden in A549 pulmonary cells and bone marrow-derived macrophages and also has an immunomodulatory effect by decreasing TNF-α, IL-6, and IL-10 production. Our results suggest milteforan as a possible alternative to treat feline sporotrichosis., Importance: Sporotrichosis is an endemic disease in Latin America caused by different species of Sporothrix. This fungus can infect domestic animals, mainly cats and eventually dogs, as well as humans. Few drugs are available to treat this disease, such as itraconazole, terbinafine, and amphotericin B, but resistance to these agents has risen in the last few years. Alternative new therapeutic options to treat sporotrichosis are essential. Here, we propose milteforan, a commercial veterinary product against dog leishmaniasis, whose active principle is miltefosine, as a possible therapeutic alternative for treating sporotrichosis. Milteforan decreases S. brasiliensis fungal burden in human and mouse cells and has an immunomodulatory effect by decreasing several cytokine production., Competing Interests: The authors declare no conflict of interest.
- Published
- 2024
- Full Text
- View/download PDF